PT2953973T - Agentes de ligação do receptor muscarínico de acetilololina e usos - Google Patents

Agentes de ligação do receptor muscarínico de acetilololina e usos

Info

Publication number
PT2953973T
PT2953973T PT147033377T PT14703337T PT2953973T PT 2953973 T PT2953973 T PT 2953973T PT 147033377 T PT147033377 T PT 147033377T PT 14703337 T PT14703337 T PT 14703337T PT 2953973 T PT2953973 T PT 2953973T
Authority
PT
Portugal
Prior art keywords
receptor binding
binding agents
acetylcholine receptor
muscarinic acetylcholine
muscarinic
Prior art date
Application number
PT147033377T
Other languages
English (en)
Inventor
Steyaert Jan
Pardon Els
Kobilka Brian
Ring Aaron
Kruse Andrew
Manglik Aasish
Original Assignee
Univ Brussel Vrije
The Board Of Trustees Of The Univ Of The Leland Stanford Junior Univ
Vib Vzw
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Brussel Vrije, The Board Of Trustees Of The Univ Of The Leland Stanford Junior Univ, Vib Vzw filed Critical Univ Brussel Vrije
Publication of PT2953973T publication Critical patent/PT2953973T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
PT147033377T 2013-02-05 2014-02-05 Agentes de ligação do receptor muscarínico de acetilololina e usos PT2953973T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361761136P 2013-02-05 2013-02-05
US201361961058P 2013-10-03 2013-10-03

Publications (1)

Publication Number Publication Date
PT2953973T true PT2953973T (pt) 2019-10-25

Family

ID=50070546

Family Applications (1)

Application Number Title Priority Date Filing Date
PT147033377T PT2953973T (pt) 2013-02-05 2014-02-05 Agentes de ligação do receptor muscarínico de acetilololina e usos

Country Status (10)

Country Link
US (3) US20150368339A1 (pt)
EP (2) EP3590578A1 (pt)
JP (2) JP2016512954A (pt)
AU (1) AU2014214054B2 (pt)
CA (1) CA2900147C (pt)
DK (1) DK2953973T3 (pt)
ES (1) ES2745772T3 (pt)
PL (1) PL2953973T3 (pt)
PT (1) PT2953973T (pt)
WO (1) WO2014122183A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201014715D0 (en) 2010-09-06 2010-10-20 Vib Vzw Nanobodies stabilizing functional conformational states of GPCRS
GB201601690D0 (en) 2016-01-29 2016-03-16 Heptares Therapeutics Ltd G proteins
WO2018126317A1 (en) * 2017-01-05 2018-07-12 Helix Biopharma Corporation Vegfr-2 car immune cells to treat cancers
JP2020506675A (ja) * 2017-01-05 2020-03-05 へリックス バイオファーマ コープ． Ｖｅｇｆｒ−２抗体
WO2019032661A1 (en) * 2017-08-09 2019-02-14 Orionis Biosciences Inc. CD8 LIAISON AGENTS
JP2021502063A (ja) 2017-10-31 2021-01-28 フエー・イー・ベー・フエー・ゼツト・ウエー 新規抗原結合性キメラタンパク質とその方法及び使用
SG11202111830UA (en) 2019-04-29 2021-11-29 Confo Therapeutics N V Chimeric proteins and methods to screen for compounds and ligands binding to gpcrs
WO2021140205A1 (en) 2020-01-10 2021-07-15 Confo Therapeutics N.V. Methods for generating antibodies and antibody fragments and libraries comprising same

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2192131A1 (en) 1992-08-21 2010-06-02 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US6838254B1 (en) 1993-04-29 2005-01-04 Conopco, Inc. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
FR2708622B1 (fr) 1993-08-02 1997-04-18 Raymond Hamers Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
DK0937140T3 (da) 1996-06-27 2008-01-28 Vlaams Interuniv Inst Biotech Antistofmolekyler, som interagerer specifikt med et målmolekyles aktive sted eller klöft
AU3596599A (en) 1998-01-26 1999-08-09 Unilever Plc Method for producing antibody fragments
AU3041100A (en) 1999-01-05 2000-07-24 Unilever Plc Binding of antibody fragments to solid supports
DE60013767T3 (de) 1999-01-19 2009-07-09 Unilever N.V. Verfahren zur herstellung von antikörperfragmenten
WO2000065057A1 (en) 1999-04-22 2000-11-02 Unilever Plc Inhibition of viral infection using monovalent antigen-binding proteins
US6479280B1 (en) 1999-09-24 2002-11-12 Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
AU1859201A (en) 1999-11-29 2001-06-12 Unilever Plc Immobilisation of proteins
WO2001044301A1 (en) 1999-11-29 2001-06-21 Unilever Plc Immobilized single domain antigen-binding molecules
ES2324280T3 (es) 2000-03-14 2009-08-04 Unilever N.V. Dominios variables de la cadena pesada de anticuerpos frente a lipasas dieteticas humanas y sus usos.
US20030190598A1 (en) 2000-05-26 2003-10-09 Jasmid Tanha Single-domain antigen-binding antibody fragments derived from llama antibodies
AU2002229639A1 (en) 2000-12-13 2002-06-24 De Haard, Johannes Joseph Wilhelmus Camelidae antibody arrays
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
US7371849B2 (en) 2001-09-13 2008-05-13 Institute For Antibodies Co., Ltd. Methods of constructing camel antibody libraries
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
AU2002360068B2 (en) 2001-12-21 2009-09-03 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Method for cloning of variable domain sequences
CA2471645A1 (en) 2002-01-03 2003-07-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Immunoconjugates useful for treatment of tumours
AU2003286004A1 (en) 2002-11-08 2004-06-07 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses therefor
JP2006520584A (ja) 2002-11-08 2006-09-14 アブリンクス エン．ヴェー． 安定化単一ドメイン抗体
GB0228210D0 (en) 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
KR101025143B1 (ko) 2002-12-31 2011-04-01 넥타르 테라퓨틱스 가수분해상으로 안정한 말레이미드－종결 중합체
CN101412759A (zh) 2003-01-10 2009-04-22 埃博灵克斯股份有限公司 治疗性多肽,其同源物、其片段及其在调节血小板介导的聚集方面的应用
ES2352697T3 (es) 2003-11-07 2011-02-22 Ablynx N.V. Anticuerpos de dominio único de camelidae vhh dirigidos contra el receptor del factor de crecimiento epidérmico y usos de los mismos.
CA2583017A1 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenerative neural diseases such as alzheimer's disease
CA2595682A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
EP2172484A3 (en) 2005-05-18 2010-05-19 Ablynx N.V. Serum albumin binding proteins
CN101213214B (zh) 2005-05-20 2014-06-25 埃博灵克斯股份有限公司 针对冯威勒布兰特因子的单一结构域vhh抗体
AU2007285695B2 (en) 2006-08-18 2012-05-24 Ablynx N.V. Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling
AU2008219216A1 (en) 2007-02-21 2008-08-28 Ablynx N.V. Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
CA2687903C (en) 2007-05-24 2016-09-13 Ablynx N.V. Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
US20110294983A1 (en) 2008-12-08 2011-12-01 Complix Nv Single-chain antiparallel coiled coil proteins
CN102257003B (zh) 2008-12-19 2017-04-05 埃博灵克斯股份有限公司 用于产生针对细胞相关抗原如p2x7、cxcr7或cxcr4的免疫球蛋白的基因免疫
WO2011083141A2 (en) 2010-01-08 2011-07-14 Ablynx Nv Method for generation of immunoglobulin sequences by using lipoprotein particles
GB201014715D0 (en) * 2010-09-06 2010-10-20 Vib Vzw Nanobodies stabilizing functional conformational states of GPCRS
DK2611826T3 (en) 2010-08-30 2017-01-09 Confometrx Inc A method and composition for the crystallization of a family-C-GPCR
US8765414B2 (en) 2011-03-15 2014-07-01 The Board Of Trustees Of The Leland Stanford Junior University GPCR fusion protein containing an N-terminal autonomously folding stable domain, and crystals of the same
CA2832739A1 (en) 2011-05-13 2012-11-22 Receptos, Inc. Novel fusion partners for the purpose of crystallizing g-protein coupled receptors
PL2951201T3 (pl) * 2013-01-30 2018-03-30 Vib Vzw Nowe polipeptydy chimeryczne do celów badań przesiewowych i odkrywania leków

Also Published As

Publication number Publication date
DK2953973T3 (da) 2019-08-12
CA2900147A1 (en) 2014-08-14
PL2953973T3 (pl) 2020-01-31
EP2953973B1 (en) 2019-07-10
EP3590578A1 (en) 2020-01-08
JP2019122378A (ja) 2019-07-25
ES2745772T3 (es) 2020-03-03
JP2016512954A (ja) 2016-05-12
WO2014122183A1 (en) 2014-08-14
JP6827485B2 (ja) 2021-02-10
WO2014122183A9 (en) 2016-05-26
EP2953973A1 (en) 2015-12-16
US20150368339A1 (en) 2015-12-24
US20180222978A1 (en) 2018-08-09
US20210340249A1 (en) 2021-11-04
AU2014214054B2 (en) 2018-10-04
CA2900147C (en) 2023-09-05
AU2014214054A1 (en) 2015-08-20

Similar Documents

Publication Publication Date Title
HK1225740A1 (zh) TGF-β受體II型變體及其用途
HK1219658A1 (zh) 吡咯並苯並二氮雜卓及其結合物
HK1219651A1 (zh) 吡咯並苯並二氮雜卓以及其結合物
HK1208038A1 (en) Anti-lgr5 antibodies and immunoconjugates lgr5
HK1214282A1 (zh) 抗- 抗體及抗體-藥物綴合物
HK1214140A1 (zh) 吡咯並苯並二氮雜卓和其結合物
HK1208687A1 (en) Rspo3 binding agents and uses thereof rspo3
IL234719A0 (en) Anti-pmel17 antibodies and immunoconjugates
HK1210947A1 (en) Anticholinergic neuroprotective composition and methods
HUE043851T2 (hu) Anti-DLL3-antitest-PBD konjugátumok és alkalmazásuk
EP2879708A4 (en) ANTIBODY AND ANTI-ETBR IMMUNOCONJUGATES
IL239643A0 (en) Converted morphines and their use
GB201317982D0 (en) Pyrrolobenzodiazepines and conjugates thereof
GB201317981D0 (en) Pyrrolobenzodiazepines and conjugates thereof
EP2829480A4 (en) FEEDING AND COUNTERING DEVICE FOR MEDICINAL PRODUCTS
EP2885318A4 (en) PEPTIDE-DENDRIMER CONJUGATES AND USES THEREOF
EP2888229A4 (en) ACETYLCHOLINE NICOTINIC A7 RECEPTOR MODULATORS AND USES THEREOF
PL2953973T3 (pl) Środki wiążące muskarynowy receptor acetylocholiny i ich zastosowania
GB2513444B (en) Improved stopper device
SG11201509448WA (en) Creamer compositions and uses thereof
EP2968554A4 (en) MET BINDER AND USES THEREOF
GB201318151D0 (en) Composition and device
EP2989089A4 (en) ACETYLCHOLINE ALPHA7 NICOTINIC RECEPTOR MODULATORS AND USES THEREOF
EP2879711A4 (en) ANTI-ETBR ANTIBODIES AND IMMUNOCONJUGATES
GB201210989D0 (en) Composition and device